profit from every $100 of sales.
$0$100
Jaguar Health
$0.42+4.73% today
-99.8% in 1 year
1-year low $0.401-year high $237.56
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Jaguar Health sold, what it kept, and what it did with the cash.
Sales went from $12.0 million in 2022 to $11.5 million in 2025, with -$53.4 million of profit last year.
SalesProfit
Jaguar Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Jaguar Health | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Jaguar Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 12 | 10 | 12 | 12 | |
| 10 | 8 | 10 | 8 | |
| -34 | -34 | -31 | -45 | |
| -33 | -33 | -37 | -52 | |
| -47 | -41 | -38 | -53 | |
| -1,129,857.14 | -29,542.20 | -4,574.15 | -803.95 | |
| 83.1% | 79.1% | 83.3% | 67.2% | |
| -287.8% | -347.5% | -263.8% | -391.9% | |
| -396.9% | -423.1% | -329.3% | -464.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 47 | 51 | 53 | 38 |
| Cash | 5 | 6 | 8 | 1 |
| Total debt | 35 | 37 | 37 | 44 |
| Total liabilities | 49 | 46 | 47 | 57 |
| -1 | 5 | 7 | -17 | |
| 0 | 0 | 0 | 0 | |
| -82.5% | -66.7% | -70.4% | -161.9% | |
| 7,222.8% | -832.5% | -528.4% | 309.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -33 | -33 | -29 | -24 | |
| 2 | – | 0 | 0 | |
| -35 | -33 | -30 | -24 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 1 |
Valuation
- –
- –
- –
- -0.0×
- 0.5×
- –
- –
- -424.5%
- -956.0%
- 0.0%
Profitability
- 67.2%
- -391.9%
- -464.2%
- -398.8%
- -180.0%
- -131.4%
- 11,326.6%
- -139.8%
- 1,969.5%
- 216.9%
Growth
- −1.3%
- –
- +119.5%
- –
- –
Financial health
- –
- -2.52
- 113.8%
- 685.2×
- 0.50
- 0.29
- 0.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 887
What analysts expect
- Average price target
- $12.98
- Range
- $12.98 – $12.98
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -6.28 | -5.08 | −23.6% |
| Aug 14, 2025 | -10.26 | -7.13 | −43.9% |
| May 15, 2025 | -16.70 | -10.82 | −54.3% |
| Mar 31, 2025 | -14.72 | -18.50 | +20.4% |
| Nov 13, 2024 | -26.25 | -59.25 | +55.7% |
| Aug 13, 2024 | -1.01 | -0.30 | −235.5% |
| May 14, 2024 | -0.90 | -0.45 | −100.0% |
| Apr 1, 2024 | -21.00 | -14.70 | −42.9% |
News
Jaguar unveils $130,000 electric vehicle two years after controversial rebrandCNBC · Oct 7, 2026Jaguar Land Rover to cut 4,000 jobs over two years in major cost-saving driveCNBC · Sep 7, 2026Jaguar Health targets mid-2027 MVID NDA filing with possible end-2027 U.S. approval, backed by up to 48% parenteral support reductionsSeeking Alpha · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
0No pass
Philip Fisher
27No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
14No pass
Terry Smith
12No pass
Questions about Jaguar Health
Is Jaguar Health a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jaguar Health AI analysis
What does Jaguar Health do?
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. It is in Biotechnology.
Does Jaguar Health pay a dividend?
No. Jaguar Health does not pay a dividend at the moment.
Is Jaguar Health stock halal?
No. Jaguar Health does not pass our halal screen: its debt is 780% of its market value, at or above the 33% limit. How we check
How has Jaguar Health stock done over the past year?
Down 99.8% over the past twelve months, to $0.42. It traded between $0.40 and $237.56 and is 99.8% below its high.
Who are Jaguar Health's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Jaguar Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.